JP2019514855A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514855A5
JP2019514855A5 JP2018551137A JP2018551137A JP2019514855A5 JP 2019514855 A5 JP2019514855 A5 JP 2019514855A5 JP 2018551137 A JP2018551137 A JP 2018551137A JP 2018551137 A JP2018551137 A JP 2018551137A JP 2019514855 A5 JP2019514855 A5 JP 2019514855A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weight
pharmaceutically active
binding polypeptide
active binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018551137A
Other languages
English (en)
Japanese (ja)
Other versions
JP7224917B2 (ja
JP2019514855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/057775 external-priority patent/WO2017167997A1/en
Publication of JP2019514855A publication Critical patent/JP2019514855A/ja
Publication of JP2019514855A5 publication Critical patent/JP2019514855A5/ja
Priority to JP2023017273A priority Critical patent/JP7496906B2/ja
Application granted granted Critical
Publication of JP7224917B2 publication Critical patent/JP7224917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018551137A 2016-03-31 2017-03-31 組成物 Active JP7224917B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023017273A JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163178.3 2016-03-31
EP16163178 2016-03-31
PCT/EP2017/057775 WO2017167997A1 (en) 2016-03-31 2017-03-31 Compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017273A Division JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Publications (3)

Publication Number Publication Date
JP2019514855A JP2019514855A (ja) 2019-06-06
JP2019514855A5 true JP2019514855A5 (OSRAM) 2020-05-14
JP7224917B2 JP7224917B2 (ja) 2023-02-20

Family

ID=55646428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018551137A Active JP7224917B2 (ja) 2016-03-31 2017-03-31 組成物
JP2023017273A Active JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023017273A Active JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Country Status (10)

Country Link
US (2) US10772839B2 (OSRAM)
EP (1) EP3435982A1 (OSRAM)
JP (2) JP7224917B2 (OSRAM)
KR (1) KR102376369B1 (OSRAM)
CN (2) CN109152738B (OSRAM)
AU (2) AU2017240190A1 (OSRAM)
CA (2) CA3019482A1 (OSRAM)
IL (1) IL261792B (OSRAM)
SG (1) SG11201807402PA (OSRAM)
WO (2) WO2017167997A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) * 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2017012662A (es) 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
WO2018060453A1 (en) * 2016-09-30 2018-04-05 Vhsquared Limited Compositions
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
EP3600416B1 (en) * 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230174554A1 (en) * 2020-05-18 2023-06-08 Shenzhen TargetRx. Inc. Solid form of macrocyclic compound, preparation therefor and use thereof
CN113768051B (zh) * 2020-06-09 2024-03-19 中粮营养健康研究院有限公司 饲料添加剂及其制备方法和其在饲料中的应用以及替抗饲料
GB202017863D0 (en) * 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010126A (en) 1934-03-19 1935-08-06 Frank L Mclaughlin Measuring and dispensing can
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
EP0725789B1 (en) * 1993-09-20 2003-03-19 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
CN1116898C (zh) * 2000-02-21 2003-08-06 湖北楚冠实业股份有限公司 一种口服免疫球蛋白制剂及其制备方法
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
AP2007004019A0 (en) * 2004-11-25 2007-06-30 Unilever Plc Heavy chain and single domain antibodies
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20080026820A1 (en) * 2006-07-05 2008-01-31 Aruze Gaming America, Inc. Slot machine and playing method thereof
WO2008031770A2 (en) 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
AU2007300221A1 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
AU2008218595B2 (en) * 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
HUE038452T2 (hu) 2007-11-13 2018-10-29 Meritage Pharma Inc Gyomor és bélrendszeri gyulladások kezelésére szolgáló kompozíciók
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN101964403A (zh) 2009-07-23 2011-02-02 比克国际(天津)有限公司 一种电池组的封装方法及电池组
EP2533814A2 (en) 2010-02-11 2012-12-19 Ablynx N.V. Delivery of immunoglobulin variable domains and constructs thereof
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
JP5931757B2 (ja) 2010-03-10 2016-06-08 インキューブ ラブズ， エルエルシー 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
EP2887960A2 (en) * 2012-08-21 2015-07-01 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
KR20150132332A (ko) 2013-03-15 2015-11-25 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 저농도 항체 제형
US20160228371A1 (en) 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3026012B1 (fr) * 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
MX2017012662A (es) * 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物

Similar Documents

Publication Publication Date Title
US11207270B2 (en) Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US20100330129A1 (en) Gastroresistant Pharmaceutical Formulations Containing Rifaximin
CN108289848A (zh) 包含urat1的有效抑制剂的药物组合物
WO2006070781A1 (ja) 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法
CN109310642B (zh) 美沙拉嗪的口服药物组合物
JP2012518655A (ja) プロトンポンプ阻害剤を含む制御放出組成物
CN101511346A (zh) 可编制的漂浮递送技术
JPH07223970A (ja) 消化管内適所放出製剤
JP2014501267A (ja) メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法
WO2023047274A1 (en) Extended release pharmaceutical compositions of dydrogesterone
US20070122480A1 (en) Sustained release formulations
TWI688411B (zh) 腸溶錠
JP6902043B2 (ja) フマル酸ジメチルを含む医薬ビーズ製剤
RU2738114C2 (ru) Пероральные фармацевтические композиции никотинамида
US20110086102A1 (en) Delayed release compositions
US20090028944A1 (en) Pharmaceutical compositions comprising mesalamine
CN113382720A (zh) 用于美沙拉嗪或其衍生物施用的固体口服药物组合物
EP3796908B1 (en) Controlled release propiverine formulations
US20230181545A1 (en) Controlled-release pharmaceutical formulations for treatment of intestinal infections
WO2009047800A2 (en) Oral controlled release composition of carvedilol
WO2011046546A1 (en) Delayed release compositions
CA2750611A1 (en) Chronotherapeutic pharmaceutical composition